More on TVTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $47.08 |
|
|||
| Open | $47.85 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $49.21 | ||||
| Day Low | $46.74 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 2,621,921 | ||||
- Travere presents long-term FILSPARI data at European kidney conference
- Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
- Travere Therapeutics (TVTX) PT Raised to $62 at Citi
- Travere Therapeutics (TVTX) PT Raised to $67 at H.C. Wainwright
- Form 8-K Travere Therapeutics, For: Jun 01
- Travere licenses BTK inhibitor from Everest for rare kidney diseases
- Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
- Travere receives patent allowance for FILSPARI use in kidney disease
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
- Form 4 Travere Therapeutics, For: May 19 Filed by: Williams Brinkley Ruth
Entities mentioned with TVTX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- PDUFA | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
